Oncology & Cancer

Blincyto approval expanded for specific leukemia

(HealthDay)—The U.S. Food and Drug Administration says it has expanded approval for Blincyto (blinatumomab) to include adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but who ...

Oncology & Cancer

The calling card of aggressive thyroid cancer

A new discovery from University of Alberta scientists represents an important milestone in the fight against thyroid cancer. In a study published in EBioMedicine and recently presented at the American Thyroid Association ...

Oncology & Cancer

First 'targeted' treatment for small cell lung cancer shows promise

Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently only diagnosed when it has spread to other parts of the body (metastasised). Five-year survival rates in SCLC, which accounts ...

page 3 from 10